Piscataway, NJ, October 25, 2023–Camber Pharmaceuticals is pleased to announce the addition of Eplerenone Tablets to its current portfolio.
Eplerenone Tablets are an aldosterone antagonist indicated for:
• Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction.
• The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Eplerenone tablets are available in 25 and 50 mg strengths in 30 and 90 count bottles.
To find out more about Eplerenone Tablets please visit www.camberpharma.com/eplerenone
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
- Camber Pharmaceuticals Launches Generic Pepcid®
- Camber Pharmaceuticals Launches Generic Wellbutrin SR®
- Camber Pharmaceuticals Launches Generic Inspra®
- Camber Pharmaceuticals Launches Generic Prezista®
- Camber Pharmaceuticals Launches Generic Neurontin Caps®
- Camber Pharmaceuticals Launches Generic Zyprexa®